clone 1g9 cat Search Results


anti tigit antibodies  (Bio X Cell)
95
Bio X Cell anti tigit antibodies
a Treatment schedule for female C57BL/6 mice injected with Vk12598 MM cells (t-VkMYC) conditioned with P.m . or vehicle (PBS) and receiving αTIGIT or IgG. b Body weight variation since tumor cell injection. Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data are presented as mean ± SD. Statistical analysis by One-way Anova. c , d M-spike appearance since tumor injection ( c ) and overall survival (OS; d ). Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data pooled from two independent experiments. Statistical analysis by Log-rank (Mantel–Cox) test. ns: not significant. Source data are provided as a Source Data file.
Anti Tigit Antibodies, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/InVivoMAb+anti-mouse+TIGIT/pmc12644586-362-0-6
Average 95 stars, based on 1 article reviews
anti tigit antibodies - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
tigit 1g9; bv650  (Becton Dickinson)
90
Becton Dickinson tigit 1g9; bv650
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Tigit 1g9; Bv650, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/anti+cd3/pmc08119420-246-240-245
Average 90 stars, based on 1 article reviews
tigit 1g9; bv650 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
icos bv421  (Becton Dickinson)
90
Becton Dickinson icos bv421
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Icos Bv421, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/annexin+v/pm35256819-658-40-47
Average 90 stars, based on 1 article reviews
icos bv421 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
capture antibody (clone 1g9)  (Abnova)
90
Abnova capture antibody (clone 1g9)
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Capture Antibody (Clone 1g9), supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/anti+type+i+collagen++col1a1+col1a2++antibodies/pmc11395628-119-1-7
Average 90 stars, based on 1 article reviews
capture antibody (clone 1g9) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cd62l fitc  (Becton Dickinson)
90
Becton Dickinson cd62l fitc
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Cd62l Fitc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/anti+cd62l/pm35256819-658-35-38
Average 90 stars, based on 1 article reviews
cd62l fitc - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cd44 bv786  (Becton Dickinson)
90
Becton Dickinson cd44 bv786
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Cd44 Bv786, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/anti+cd14/pmc08960412__43018_2022_334_MOESM2_ESM-32-49-56
Average 90 stars, based on 1 article reviews
cd44 bv786 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
icos pe 1/100  (Becton Dickinson)
90
Becton Dickinson icos pe 1/100
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Icos Pe 1/100, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/anti+icos/pm35256819-659-54-61
Average 90 stars, based on 1 article reviews
icos pe 1/100 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
tim3 bv650 1/50 5d12  (Becton Dickinson)
90
Becton Dickinson tim3 bv650 1/50 5d12
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Tim3 Bv650 1/50 5d12, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/tim+3+antibody/pmc08960412__43018_2022_334_MOESM2_ESM-33-89-96
Average 90 stars, based on 1 article reviews
tim3 bv650 1/50 5d12 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cd62l bv510 1/100  (Becton Dickinson)
90
Becton Dickinson cd62l bv510 1/100
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Cd62l Bv510 1/100, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/anti+cd27/pm35256819-659-38-45
Average 90 stars, based on 1 article reviews
cd62l bv510 1/100 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cd25 bv605 1/50  (Becton Dickinson)
90
Becton Dickinson cd25 bv605 1/50
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Cd25 Bv605 1/50, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/cd25+bv421+antibody/pm35256819-659-98-105
Average 90 stars, based on 1 article reviews
cd25 bv605 1/50 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
icos pe 1/100 7e.17g9  (Becton Dickinson)
90
Becton Dickinson icos pe 1/100 7e.17g9
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Icos Pe 1/100 7e.17g9, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/anti+icos++7e+17g9+/pmc08960412__43018_2022_334_MOESM2_ESM-33-54-61
Average 90 stars, based on 1 article reviews
icos pe 1/100 7e.17g9 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
tim3 bv650 1/50  (Becton Dickinson)
90
Becton Dickinson tim3 bv650 1/50
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Tim3 Bv650 1/50, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clone+1g9+cat/cd4+bv650+antibody/pm35256819-659-93-96
Average 90 stars, based on 1 article reviews
tim3 bv650 1/50 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


a Treatment schedule for female C57BL/6 mice injected with Vk12598 MM cells (t-VkMYC) conditioned with P.m . or vehicle (PBS) and receiving αTIGIT or IgG. b Body weight variation since tumor cell injection. Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data are presented as mean ± SD. Statistical analysis by One-way Anova. c , d M-spike appearance since tumor injection ( c ) and overall survival (OS; d ). Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data pooled from two independent experiments. Statistical analysis by Log-rank (Mantel–Cox) test. ns: not significant. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma

doi: 10.1038/s41467-025-65312-y

Figure Lengend Snippet: a Treatment schedule for female C57BL/6 mice injected with Vk12598 MM cells (t-VkMYC) conditioned with P.m . or vehicle (PBS) and receiving αTIGIT or IgG. b Body weight variation since tumor cell injection. Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data are presented as mean ± SD. Statistical analysis by One-way Anova. c , d M-spike appearance since tumor injection ( c ) and overall survival (OS; d ). Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data pooled from two independent experiments. Statistical analysis by Log-rank (Mantel–Cox) test. ns: not significant. Source data are provided as a Source Data file.

Article Snippet: Anti-TIGIT antibodies (Clone 1G9, Cat. BE0274, BioxCell) or isotype control antibodies (mouse IgG1 isotype; Cat. BE0083, BioxCell; 200 μg/dose) were administered twice per week to t-VkMYC mice pretreated as described above. t-VkMYC mice were weekly bled for M-spike quantification.

Techniques: Injection

a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.

Journal: Nature Communications

Article Title: Antigen-driven EGR2 expression is required for exhausted CD8 + T cell stability and maintenance

doi: 10.1038/s41467-021-23044-9

Figure Lengend Snippet: a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: The following antibodies were used for staining (purchased from Biolegend unless otherwise stated): CD8α (clone 53-6.7; PerCP (1/100, Cat. no. 100732), BV421 (1/200, Cat. no. 100738), BUV395 (1/200, BD Biosciences Cat. no. 563786) and BUV805 (1/200, BD Biosciences Cat. no. 563786)), CD44 (clone IM7; Pacific Blue (1/400, Cat. no. 103020), BUV737 (1/1000, BD Biosciences Cat. no. 612799)), CD107a (clone 1D4B; FITC (1/400, Cat. no. 121606)), IFNγ (clone XMG1.2; PE-Cy7 (1/2000, eBioscience Cat. no. 25-7311-41), TNFα (clone MP6-XT22; PE (1/2000, Cat. no. 506306)), IL-2 (clone JES6-5H4; APC (1/100, eBioscience Cat. no. 17-7021-82)), CD45.1 (clone A20; FITC (1/200, BD Biosciences Cat. no. 553775)), CD45.2 (clone 104; BUV395 (1/200, BD Biosciences Cat. no. 564616)), Ly6C (clone AL21; FITC (1/200, BD Biosciences Cat. no. 553104)), PD-1 (clone 29F.1A12; BV785 (1/100, Cat. no. 135225)), Tim3 (clone RMT3-23; BV605 (1/100, Cat. no. 119721)), 2B4 (clone 2B4; FITC (1/50, BD Biosciences Cat. no. 553305)), Lag3 (clone C9B7W; PE (1/100, Cat. no. 125208)), CD160 (clone 7H1; PE-Cy7 (1/100, Cat. no. 143010)), Egr2 (clone erongr2; PE (1/50, eBioscience Cat. no. 143010)), TCF1 (clone C63D9; unconjugated (1/100, Cell Signaling Technologies Cat. no. 2203S) followed by a secondary antibody (Goat anti-Rabbit Alexa594 (1/1000, Invitrogen Cat. no. A11012))), CXCR5 (clone 2G8; BV421 (1/25, BD Biosciences Cat. no. 562856)), Slamf6 (clone 13G3; PE (1/200, BD Biosciences Cat. no. 561540), BV421 (1/200, BD Biosciences Cat. no. 740090)), CD101 (clone Moushi101; PE-Cy7 (1/200, eBioscience Cat. no. 25-1011-82)), CD127 (clone A7R34; PE-Cy7 (1/100, Cat. no. 135014)), TIGIT (clone 1G9; BV650 (1/100, BD Biosciences Cat. no. 744213)), Ly6A/E (clone E13-161.7; PE (1/200, BD Biosciences Cat. no. 553336)), GzmB (clone GB11; PE (1/200, eBioscience Cat. no. GRB04)), FR4 (clone eBio12A5; PE-Cy7 (1/100, eBioscience Cat. no. 25-5445-82)), IL-10Rα (clone 1B1.3a; PE (1/100, Cat. no. 112706)), KLRG1 (clone 2F1; FITC (1/200, eBioscience Cat. no. 11-5893-82)), CD62L (clone MEL-14; APC-Cy7 (1/200, Cat. no. 104428)), Eomes (clone Dan11mag; Alexa488 (1/50, eBioscience Cat. no. 53-4875-82)), ppErk1/2 (clone 197G2; Alexa647 (1/100, Cell Signaling Technologies Cat. no. 13148S)), and pS6 (clone D57.2.2E; Alexa488 (1/100, Cell Signaling Technologies Cat. no. 4803S)).

Techniques: Staining, Infection, Generated, Expressing, Two Tailed Test, MANN-WHITNEY